- Drugs
- Thursday, 12 Dec 2019
United Cannabis Corporation Receives Notice of Allowance for New Patent Covering Methods of Preparing and Using Cannabinoid Formulations
United Cannabis Corporation (OTCBB: CNAB) (the "Company" or "United Cannabis") announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for its application for a new patent that claims methods of using and preparing cannabinoid formulations. The allowed application will mature into an issued patent once the issue fee is paid to the USPTO.
The allowed application is a divisional of the application that was previously allowed by the USPTO and which matured into the Company's US Patent No. 9,730,911 (the "'911 Patent"). The '911 Patent was issued on August 15, 2017.
Jesús Vázquez, Vice President and General Counsel of the Company and who was recently named as one of the "50 Most Influential People in IP 2019: Industry Leaders" by the publication "Managing Intellectual Property," commented: "The new patent will compliment and will have the same priority date as our '911 Patent. It will be a valuable addition to the Company's patent portfolio."
Vázquez added: "The USPTO concluded that the claims in the new patent "are neither anticipated nor rendered obvious over the record." This is significant because the materials in the "record" that were reviewed by the USPTO include materials that our adversary in pending litigation has argued invalidate our '911 Patent. If those materials do not invalidate the claims in the new patent, they do not invalidate the claims in the '911 Patent."
Earnie Blackmon, Chief Executive Officer of United Cannabis, commented: "This development further confirms and protects our innovative approach to the advancement and use of cannabinoids for medical applications. As the broader medical and regulatory communities begin to recognize the opportunities within the sector it is increasingly important that we protect the innovations we have developed and the investment we have made along the way."
Related Industry Updates
Epilepsy Drugs Market is expected to reach US$ 10,705.48 million by 2030
Nov 06, 2023
Zongertinib Gains Accelerated FDA Approval as First Oral Targeted Option for HER2-Mutant Lung Cancer
Aug 26, 2025
Cannabis Market is Heating Up Faster Than Branders Can Define It
Oct 10, 2019
Aphria Inc.'s Jamaican Subsidiary, Marigold, Receives Retail Herb House Licence
Sep 17, 2019
Pet Anthelmintic Drugs Market - Important Changes in Industry Dynamics
Mar 17, 2021
Companion Animal Specialty Drugs Market To Record Ascending Growth By 2027
Nov 26, 2020
Myopia Treatment Market is expected to reach US$ 19,571.85 million by 2030
Jan 10, 2024